You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
UK immigrant screening is inversely related to regional tuberculosis burden
  1. Manish Pareek1,2,
  2. Ibrahim Abubakar3,4,
  3. Peter J White5,6,
  4. Geoffrey P Garnett6,
  5. Ajit Lalvani2
  1. 1Department of Infectious Disease Epidemiology, Imperial College London, London, UK
  2. 2Tuberculosis Research Unit, Department of Respiratory Medicine, National Heart and Lung Institute, Imperial College London, London, UK
  3. 3Tuberculosis Section, Centre for Infections, Health Protection Agency, London, UK
  4. 4School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK
  5. 5Modelling and Economics Unit, Centre for Infections, Health Protection Agency, London, UK
  6. 6MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, London, UK
  1. Correspondence to Professor Ajit Lalvani, Chair of Infectious Diseases, Director, Tuberculosis Research Unit, Department of Respiratory Medicine, National Heart and Lung Institute, Imperial College London, Norfolk Place, London W2 1PG, UK; a.lalvani{at}imperial.ac.uk

https://doi.org/10.1136/thx.2010.152280

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the editorial by Moore-Gillon et al,1 which advocated a more comprehensive system of immigrant screening/treatment for latent tuberculosis infection (LTBI) as a means of augmenting tuberculosis (TB) control in the UK.

    A recent comprehensive, national evaluation of local TB services/primary care organisations(PCOs) in the UK, which provides key insights into UK screening practices,2 found that the existing …

    View Full Text

    Footnotes

    • Linked articles 156968, 152868.

    • Competing interests AL is inventor for patents underpinning T cell-based diagnosis. The IFN-gamma ESAT-6/CFP-10 ELISpot was commercialised by an Oxford University spin-out company (T.SPOT-TB, Oxford Immunotec Ltd, Abingdon, UK) in which Oxford University and AJ have minority shares of equity and royalty entitlements.

    • Provenance and peer review Not commissioned; not externally peer reviewed.

    Linked Articles